KMT2A and thymoma: Recently, oncogenic rearrangements involving Lysine methyltransferase 2A (KMT2A), a frequent fusion partner in some acute leukemias, have been reported in solid tumors, including types B2 and B3 thymomas and soft tissue sarcomas [3–7].